CTIS2023-503647-34-00进行中（未招募）1 期
D.01.01.2.03
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 92
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid TumoursAdvanced or refractory solid tumoursCTIS2023-504897-39-00Deuteroncology60
进行中（未招募）
1 期
A phase 2 evaluation for patients who undego kidney transplant requires long term theraphy that suppress immune response to prevent damage rejection by stopping the immune system from attacking the healthy tissues in the body.EUCTR2013-002090-21-ATBristol-Myers Squibb International Corporation240
招募中
1 期
A Study of NB003 in Patients With Advanced MalignanciesCTIS2022-502401-15-00ingbo Newbay Technology Development Co. Ltd.290
进行中（未招募）
1 期
Treatment of cancer with Immune Checkpoint Inhibition therapy boosted by High Intensity Focused Ultrasound Histotripsy (the iFOCUS study)Metastatic or unresectable solid malignancies. Standard of care treatment options must not be available or not be considered feasible. Patients must have a primary tumor or metastasis that is suitable for HIFU-HT treatment.CTIS2023-509210-10-00niversitair Medisch Centrum Utrecht24
进行中（未招募）
1 期
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001Chronic Hepatitis BCTIS2023-504288-18-00Zhejiang Yaoyuan Biotechnology Co. Ltd.119